Welcome to our dedicated page for VITASPRING BIOMEDICAL CO. LTD. SEC filings (Ticker: VSBC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on VITASPRING BIOMEDICAL CO. LTD.'s stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into VITASPRING BIOMEDICAL CO. LTD.'s regulatory disclosures and financial reporting.
VITASPRING BIOMEDICAL CO., LTD. (VSBC) reports a leadership transition effective late on September 7, 2026. At 11:58 p.m. Pacific Time, Dr. Ssu‑Chuan Lai resigned as Chairperson of the Board, Chief Executive Officer, President, Chief Financial Officer, Secretary, and as a director. The company states that Dr. Lai’s resignation was not the result of any disagreement relating to operations, policies, or practices, and her resignation letter is included as an exhibit.
Immediately before this, Dr. Lai, as the sole director, elected Shao‑Hsiang Shih as a director at 11:56 p.m. and designated him Chairman at 11:57 p.m., and appointed Jing‑Zhou Chen as Chief Executive Officer, President, Chief Financial Officer, and Secretary at 11:57 p.m. Mr. Chen is designated as principal executive, financial, and accounting officer. Both Mr. Chen and Mr. Shih currently receive no compensation for their roles unless later determined by the board, have no disclosed related-party transactions or family relationships with existing officers or directors, and are entitled to indemnification and advancement of expenses to the fullest extent permitted by Nevada law and the company’s governing documents.
VitaSpring Biomedical Co., Ltd. reported no revenue for the three and six months ended July 31, 2025, as it remains a development-stage company focused on cell-based regenerative medicine concepts. The company recorded a net loss of $110,845 for the quarter and $191,386 for the six-month period, narrower than the prior-year losses due mainly to the elimination of lease and stock-based compensation costs.
Liquidity is extremely strained: cash was only $799, against current liabilities of $4,223,606, creating a working capital deficit of $4,215,713 and a stockholders’ deficit of $4,206,586. Related-party obligations are significant, including $2,411,000 of accounts payable to a related-party vendor and $917,020 of advances from a former CEO and other related parties. Management and the notes state that these conditions raise substantial doubt about the company’s ability to continue as a going concern, and that continued operations depend on securing additional financing and ongoing related-party support.
The company currently has no active commercial operations, no R&D spending, and has not initiated clinical trials or obtained regulatory approvals. Internal control over financial reporting was deemed ineffective due to a material weakness tied to limited personnel and lack of SEC-reporting expertise, with remediation plans dependent on future funding. As of June 17, 2026, there were 207,030,030 common shares issued and outstanding.